UPDATE 1-Glaxo two-in-one prostrate drug approved in Europe

* Duodart backing comes 10 days after Swiss approval

(Adds detail)

LONDON, March 31 (Reuters) - Duodart, a two-in-one prostrate drug from GlaxoSmithKline (GSK.L), has been approved in Europe, the British drugmaker said on Wednesday.

The backing -- from Germany but which applies across the European Union -- came 10 days after the drug received the green light in Switzerland, its first European market. [ID:nLDE62L0LU]

Duodart is the first fixed dose combination for prostrate enlargement, or benign prostatic hyperplasia (BPH), which is an increasingly common problem for men as they age.

It combines Glaxo's established drug Avodart, or dutasteride with Astellas Pharma's (4503.T) off patent product Flomax, or tamsulosin.

(Reporting by Paul Sandle; editing by Rhys Jones)